Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Subscribe To Our Newsletter & Stay Updated
